{
    "root": "3540f59e-f085-8760-e063-6394a90aae82",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Aripiprazole",
    "value": "20250516",
    "ingredients": [
        {
            "name": "EDETATE DISODIUM",
            "code": "7FLD91C86K"
        },
        {
            "name": "FRUCTOSE",
            "code": "6YSS42VSEV"
        },
        {
            "name": "GLYCERIN",
            "code": "PDC6A3C0OX"
        },
        {
            "name": "MALIC ACID",
            "code": "817L1N4CKP"
        },
        {
            "name": "METHYLPARABEN",
            "code": "A2I8C7HI9T"
        },
        {
            "name": "ORANGE",
            "code": "5EVU04N5QU"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "PROPYLPARABEN",
            "code": "Z8IX2SC1OH"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "ARIPIPRAZOLE",
            "code": "82VFR53I78"
        }
    ],
    "indications": "Aripiprazole oral solution is indicated for the treatment of:\n                  \n                     Schizophrenia\n  \n   [see\n   \n    Clinical Studies (14.1)]\n  \n   \n                     \n                     Acute Treatment of Manic and Mixed Episodes associated with Bipolar I Disorder\n  \n   [see\n   \n    Clinical Studies (14.2)]\n  \n   \n                     \n                     Adjunctive Treatment of Major Depressive Disorder\n  \n   [see\n   \n    Clinical Studies (14.3)]\n  \n   \n                     \n                     Irritability Associated with Autistic Disorder\n  \n   [see\n   \n    Clinical Studies (14.4)]\n  \n   \n                     \n                     Treatment of Tourette’s Disorder\n  \n   [see\n   \n    Clinical Studies (14.5)]",
    "contraindications": "Initial Dose Recommended Dose Maximum Dose Schizophrenia - adults ( 2.1 ) 10 to 15 mg/day 10 to 15 mg/day 30 mg/day Schizophrenia - adolescents ( 2.1 ) 2 mg/day 10 mg/day 30 mg/day Bipolar mania - adults: monotherapy ( 2.2 ) 15 mg/day 15 mg/day 30 mg/day Bipolar mania - adults: adjunct to lithium or valproate ( 2.2 ) 10 to 15 mg/day 15 mg/day 30 mg/day Bipolar mania - pediatric patients: monotherapy or as an adjunct to lithium or valproate ( 2.2 ) 2 mg/day 10 mg/day 30 mg/day Major Depressive Disorder - Adults adjunct to antidepressants ( 2.3 ) 2 to 5 mg/day 5 to 10 mg/day 15 mg/day Irritability associated with autistic disorder - pediatric patients ( 2.4 ) 2 mg/day 5 to 10 mg/day 15 mg/day Tourette’s disorder - ( 2.5 ) Patients < 50 kg 2 mg/day 5 mg/day 10 mg/day Patients > 50 kg 2 mg/day 10 mg/day 20 mg/day Oral formulations: Administer once daily without regard to meals ( 2 ) Known CYP2D6 poor metabolizers: Half of the usual dose ( 2.7 )",
    "warningsAndPrecautions": null,
    "adverseReactions": "Aripiprazole oral solution is contraindicated in patients with a history of a hypersensitivity reaction to aripiprazole. Reactions have ranged from pruritus/urticaria to anaphylaxis\n \n  [see\n  \n   Adverse Reactions (6.2)]\n \n  ."
}